OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Jared Weiss(University of North Carolina at Chapel Hill), S. Wang(Pfizer (United States)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Tiziana Usari(Pfizer (Italy)), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Rebecca S. Heist(Massachusetts General Hospital), Si Li(Pfizer (United States)), Liza C. Villaruz(University of Pittsburgh Medical Center), D. Ross Camidge(University of Colorado Denver), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Danielle Murphy(Pfizer (United States)), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 35
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k